Literature DB >> 26307825

Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection.

Abhijit A Date, Annemaria Shibata, Emily McMullen, Krista La Bruzzo, Patrick Bruck, Michael Belshan, You Zhou, Christopher J Destache.   

Abstract

The objective of this investigation was to develop and evaluate a nano-microbicide containing a combination of cellulose acetate phthalate (HIV-1 entry inhibitor) and efavirenz (anti-HIV agent) for HIV prophylaxis. Cellulose acetate phthalate-efavirenz combination nanoparticles (CAP-EFV-NPs) were fabricated by the nanoprecipitation method and were characterized for particle size, zeta potential and encapsulation efficiency of efavirenz. CAP-EFV-NPs were incorporated into a thermosensitive gel (CAP-EFV-NP-Gel). CAP-EFV-NPs, CAP-EFV-NP-Gel and efavirenz solution were evaluated for cytotoxicity to HeLa cells and for in vitro short-term (1-day) and long-term (3-day) prophylaxis against HIV-1 infection in TZM-bl cells. CAP-EFV-NPs had size < 100 nm, negative surface charge and encapsulation efficiency of efavirenz was > 98%. CAP-EFV-NPs and CAP-EFV-NP-Gel were significantly less toxic (P < 0.01) to HeLa cells as compared to efavirenz solution. CAP-EFV-NPs showed significantly higher prophylactic activity (P < 0.01) against HIV-1 infection to TZM-bl cells as compared to efavirenz solution and blank CAP nanoparticles. CAP-EFV-NP-Gel can be a promising nano-microbicide for long-term HIV prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26307825      PMCID: PMC5996982          DOI: 10.1166/jbn.2015.1942

Source DB:  PubMed          Journal:  J Biomed Nanotechnol        ISSN: 1550-7033            Impact factor:   4.099


  33 in total

1.  Design of a "microbicide" for prevention of sexually transmitted diseases using "inactive" pharmaceutical excipients.

Authors:  A R Neurath; N Strick; Y Y Li; K Lin; S Jiang
Journal:  Biologicals       Date:  1999-03       Impact factor: 1.856

2.  Kinetics and mechanism of hydrolysis of efavirenz.

Authors:  Michael B Maurin; Susan M Rowe; Karl Blom; Michael E Pierce
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

3.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

Review 4.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

5.  Electrospun cellulose acetate phthalate fibers for semen induced anti-HIV vaginal drug delivery.

Authors:  Chaobo Huang; Stefaan J Soenen; Ellen van Gulck; Guido Vanham; Joanna Rejman; Serge Van Calenbergh; Chris Vervaet; Tom Coenye; Hans Verstraelen; Marleen Temmerman; Jo Demeester; Stefaan C De Smedt
Journal:  Biomaterials       Date:  2011-10-21       Impact factor: 12.479

6.  Preparation and characterization of triclosan nanoparticles for periodontal treatment.

Authors:  E Piñón-Segundo; A Ganem-Quintanar; V Alonso-Pérez; D Quintanar-Guerrero
Journal:  Int J Pharm       Date:  2005-04-27       Impact factor: 5.875

Review 7.  Microbicides and HIV prevention: lessons from the past, looking to the future.

Authors:  Georgina C Morris; Charles J N Lacey
Journal:  Curr Opin Infect Dis       Date:  2010-02       Impact factor: 4.915

8.  Expression of cytochrome P450 and microsomal epoxide hydrolase in cervical and oral epithelial cells immortalized by human papillomavirus type 16 E6/E7 genes.

Authors:  F M Farin; L G Bigler; D Oda; J K McDougall; C J Omiecinski
Journal:  Carcinogenesis       Date:  1995-06       Impact factor: 4.944

9.  Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.

Authors:  Christopher J Destache; Todd Belgum; Keith Christensen; Annemarie Shibata; Akhilesh Sharma; Alekha Dash
Journal:  BMC Infect Dis       Date:  2009-12-09       Impact factor: 3.090

Review 10.  Efavirenz: a decade of clinical experience in the treatment of HIV.

Authors:  Franco Maggiolo
Journal:  J Antimicrob Chemother       Date:  2009-09-18       Impact factor: 5.790

View more
  12 in total

1.  Pharmaceutically Acceptable Carboxylic Acid-Terminated Polymers Show Activity and Selectivity against HSV-1 and HSV-2 and Synergy with Antiviral Drugs.

Authors:  Tejabhiram Yadavalli; Sudipta Mallick; Pratikkumar Patel; Raghuram Koganti; Deepak Shukla; Abhijit A Date
Journal:  ACS Infect Dis       Date:  2020-10-20       Impact factor: 5.084

Review 2.  Nanotechnology approaches for delivery of cytochrome P450 substrates in HIV treatment.

Authors:  Yuqing Gong; Pallabita Chowdhury; Prashanth K B Nagesh; Theodore J Cory; Chelsea Dezfuli; Sunitha Kodidela; Ajay Singh; Murali M Yallapu; Santosh Kumar
Journal:  Expert Opin Drug Deliv       Date:  2019-07-24       Impact factor: 6.648

Review 3.  On-demand microbicide products: design matters.

Authors:  Sravan Kumar Patel; Lisa Cencia Rohan
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

4.  Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.

Authors:  Subhra Mandal; Pavan K Prathipati; Guobin Kang; You Zhou; Zhe Yuan; Wenjin Fan; Qingsheng Li; Christopher J Destache
Journal:  AIDS       Date:  2017-02-20       Impact factor: 4.177

5.  Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.

Authors:  Christopher J Destache; Subhra Mandal; Zhe Yuan; Guobin Kang; Abhijit A Date; Wuxun Lu; Annemarie Shibata; Rachel Pham; Patrick Bruck; Michael Rezich; You Zhou; Renuga Vivekanandan; Courtney V Fletcher; Qingsheng Li
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

6.  Nanoparticle Encapsulation for Antiretroviral Pre-Exposure Prophylaxis.

Authors:  Karl Khandalavala; Subhra Mandal; Rachel Pham; Christopher J Destache; Annemarie Shibata
Journal:  J Nanotechnol Mater Sci       Date:  2017-08-07

7.  Cellulose Acetate Phthalate and Antiretroviral Nanoparticle Fabrications for HIV Pre-Exposure Prophylaxis.

Authors:  Subhra Mandal; Karl Khandalavala; Rachel Pham; Patrick Bruck; Marisa Varghese; Andrew Kochvar; Ashley Monaco; Pavan Kumar Prathipati; Christopher Destache; Annemarie Shibata
Journal:  Polymers (Basel)       Date:  2017-09-07       Impact factor: 4.329

8.  Enzyme Responsive Vaginal Microbicide Gels Containing Maraviroc and Tenofovir Microspheres Designed for Acid Phosphatase-Triggered Release for Pre-Exposure Prophylaxis of HIV-1: A Comparative Analysis of a Bigel and Thermosensitive Gel.

Authors:  Sabdat Ozichu Ekama; Margaret O Ilomuanya; Chukwuemeka Paul Azubuike; James Babatunde Ayorinde; Oliver Chukwujekwu Ezechi; Cecilia Ihuoma Igwilo; Babatunde Lawal Salako
Journal:  Gels       Date:  2021-12-24

Review 9.  Novel Antiretroviral Therapeutic Strategies for HIV.

Authors:  Rita F Cunha; Sandra Simões; Manuela Carvalheiro; José M Azevedo Pereira; Quirina Costa; Andreia Ascenso
Journal:  Molecules       Date:  2021-08-31       Impact factor: 4.411

Review 10.  Advancements in prophylactic and therapeutic nanovaccines.

Authors:  Prateek Bhardwaj; Eshant Bhatia; Shivam Sharma; Nadim Ahamad; Rinti Banerjee
Journal:  Acta Biomater       Date:  2020-04-05       Impact factor: 10.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.